뇌신경계 중환자실 전담 약사의 활동에 따른 약물 조정 효과 및 회피비용 분석 = Effects of Medication Reconciliation and Cost Avoidance Analysis by Clinical Pharmacists in a Neurocritical Care Unit

다국어 초록 (Multilingual Abstract)

Background: The role of clinical pharmacists in medication therapy to improve clinical and economic outcomes has been reported in the literature. This study was conducted to analyze the changes in details of medication interventions before and after the introduction of clinical pharmacists into the care of neurocritical care unit (NCU) patients, and to evaluate the economic effects of clinical pharmacists by calculating the avoidance cost.
Methods: A retrospective study was conducted reviewing the electronic medical records from June 2013 to May 2014 (before), and from June 2016 to May 2017 (after). We calculated the number and rates of intervention, the acceptance rates of it, and also reviewed the list of interventions. We calculated avoidance cost if there was no intervention.
Results: The monthly mean number of interventions increased from 8.0 (±5.7) to 31.7 (±12.8) (P <0.001) and the frequency of intervention also increased from 0.8% to 1.6% (P =0.003). The most frequently provided pharmacist intervention was nutritional support before introduction of clinical pharmacists and discussions on the medication plan after. The number of classified interventions was 14 before introduction of clinical pharmacist services and 33 after. The calculated cost avoidance associated with a clinical pharmacists’ integration was 77,990,615 won per year.
Conclusions: Introduction of clinicals pharmacist into the NCU was associated with increased intervention rates and expanded types of clinical interventions. The cost avoidance achieved by the pharmacists’ interventions can be further explored to evaluate if similar expansions of pharmacists’ services achieve similar results in other settings.

참고문헌 (Reference)

1 강철환, "중환자실의 중증도 보정 사망률 변이" 대한마취통증의학회 57 (57): 698-703, 2009

2 강민경, "외과계중환자실 담당약사의 약물유해반응 예방에 대한 처방중재효과" 대한중환자의학회 28 (28): 17-24, 2013

3 신상미, "외과계 중환자실 전담약사 유무에 따른 중재활동 변화 및 회피비용 분석" 한국병원약사회 34 (34): 401-409, 2017

4 박태영, "담당약사의 처방중재활동에 대한 약물유해반응 예방의 비교 분석" 한국병원약사회 31 (31): 638-643, 2014

5 최재희, "내과계 중환자실 약료 서비스 도입과 약물상호작용 모니터링" 한국임상약학회 25 (25): 138-144, 2015

6 이종혜, "개정된 원내 노인부적절약물 목록을 활용한 입원환자의 약물 평가 및 임상적 중재에 의한 회피비용 분석" 한국병원약사회 31 (31): 629-637, 2014

7 Kane SL, "The impact of critical care pharmacists on enhancing patient outcomes" 29 : 691-698, 2003

8 Kim YS, "Role of the intensive care unit pharmacist" 28 : 105-110, 2011

9 Cullen DJ, "Preventable adverse drug events in hospitalized patients:a comparative study of intensive care and general care units" 25 : 1289-1297, 1997

10 Chung J, "Preliminary study for economic evaluation of clinical pharmacist intervention" 28 : 327-336, 2011

11 Klopotowska JE, "On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study" 14 : R174-, 2010

12 Bond CA, "Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing" 21 : 129-141, 2001

13 LeBlanc JM, "International critical care hospital pharmacist activities" 34 : 538-542, 2008

14 Nesbit TW, "Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model" 58 : 784-790, 2001

15 Zaidi ST, "Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital" 25 : 299-302, 2003

16 Mutnick AH, "Cost savings and avoidance from clinical interventions" 54 : 392-396, 1997

17 Kopp BJ, "Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist" 64 : 2483-2487, 2007

18 World Health Organization, "Conceptual framework for the international classification for patient safety, version 1.1: final technical report" WHO 1-149, 2009

19 Lee AJ, "Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center" 59 : 2070-2077, 2002

20 MacLaren R, "Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections" 36 : 3184-3189, 2008

21 Kane-Gill S, "Adverse-drugevent rates for high-cost and high-use drugs in the intensive care unit" 63 : 1876-1881, 2006

22 Jeong JH, "A dedicated neurological intensive care unit offers improved outcomes for patients with brain and spine injuries" 20 : 1-5, 2017